bioAffinity Technologies, Inc. 8-K

What Happened
bioAffinity Technologies, Inc. filed a Form 8-K (Item 8.01) on February 9, 2026 announcing that Dr. David Ost, MD, MPH; Dr. Daniel Sterman, MD; and Dr. J. Scott Ferguson, MD have been appointed to the company’s Medical and Scientific Advisory Board. The company attached a press release dated February 9, 2026 as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 9, 2026 (Form 8-K, Item 8.01).
• Appointees: David Ost, MD, MPH; Daniel Sterman, MD; J. Scott Ferguson, MD.
• Announcement format: press release included as Exhibit 99.1 in the 8-K.
• Company: bioAffinity Technologies, Inc., a Delaware corporation.

Why It Matters
Adding recognized medical and scientific advisors can strengthen the company’s clinical and scientific credibility and support product development, clinical trials, and regulatory engagement. For investors, appointments to an advisory board are a non-financial signal that the company is building expertise around its medical programs; the filing does not include financial impacts or changes in management compensation.